Search
Descriptor English: Tumor Lysis Syndrome
Descriptor Spanish: Síndrome de Lisis Tumoral
Descriptor Portuguese: Síndrome de Lise Tumoral
Descriptor French: Syndrome de lyse tumorale
Entry term(s): Syndrome, Tumor Lysis
Syndrome, Tumour Lysis
Syndromes, Tumor Lysis
Syndromes, Tumour Lysis
Tumor Lysis Syndromes
Tumour Lysis Syndrome
Tumour Lysis Syndromes
Tree number(s): C15.604.515.880
C20.683.515.950
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D015275
Scope note: A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
Annotation: lymphoproliferative disord caused by anticancer drugs; coord IM with /etiol (not /chem ind) + anticancer drug /adv eff (IM) + required neopl coords /drug ther (IM or NIM) if pertinent
Allowable Qualifiers: BL blood
CF cerebrospinal fluid
CL classification
CN congenital
CO complications
DG diagnostic imaging
DH diet therapy
DI diagnosis
DT drug therapy
EC economics
EH ethnology
EM embryology
EN enzymology
EP epidemiology
ET etiology
GE genetics
HI history
IM immunology
ME metabolism
MI microbiology
MO mortality
NU nursing
PA pathology
PC prevention & control
PP physiopathology
PS parasitology
PX psychology
RH rehabilitation
RT radiotherapy
SU surgery
TH therapy
UR urine
VE veterinary
VI virology
Previous Indexing: Antineoplastic Agents, Combined/adverse effects/therapeutic use (1980-1988)
Antineoplastic Agents/therapeutic use (1984-1988)
Burkitt's Lymphoma/complications (1980-1988)
Public MeSH Note: 89
History Note: 89
Related: Tumor Necrosis Factor-alpha MeSH
DeCS ID: 23852
Unique ID: D015275
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 1989/01/01
Date of Entry: 1988/05/19
Revision Date: 2004/07/20
Tumor Lysis Syndrome - Preferred
Concept UI M0023515
Scope note A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
Preferred term Tumor Lysis Syndrome
Entry term(s) Syndrome, Tumor Lysis
Syndrome, Tumour Lysis
Syndromes, Tumor Lysis
Syndromes, Tumour Lysis
Tumor Lysis Syndromes
Tumour Lysis Syndrome
Tumour Lysis Syndromes



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey